Sign In
Buy SNDX
$18.34
-0.0500 (-0.272%)
At Close: Jun 03, 2026
Syndax Pharmaceuticals: Positive Axatilimab Phase 2 Results
10:42am, Friday, 08'th Sep 2023
Syndax is making strides in the adoption of entinostat, a cancer therapeutic used in combination with immune checkpoint therapies. Syndax reported an increase in operating expenses in Q2 2023, but rem
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2023 Earnings Call Transcript
09:08pm, Saturday, 05'th Aug 2023
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Sharon Klahre - Head, IR Michael Metzger - CEO Neil Gallagher - President &
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2023 Earnings Call Transcript
10:53pm, Monday, 08'th May 2023
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive Offi
Syndax to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 8, 2023
07:00am, Monday, 01'st May 2023
WALTHAM, Mass. , May 1, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today annou
Incyte's (INCY) Q4 Earnings, Revenues Top on Jakafi, Opzelura
03:50pm, Tuesday, 07'th Feb 2023 Zacks Investment Research
Incyte (INCY) reports better-than-expected Q4 results on strong demand for lead drug Jakafi and recently approved Opzelura.
Recent Price Trend in Syndax (SNDX) is Your Friend, Here's Why
01:50pm, Monday, 06'th Feb 2023 Zacks Investment Research
Syndax (SNDX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "
Recent Price Trend in Syndax (SNDX) is Your Friend, Here's Why
10:32am, Monday, 06'th Feb 2023
Syndax (SNDX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "
Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?
07:02pm, Friday, 03'rd Feb 2023 Zacks Investment Research
On Vertex Pharmaceuticals' (VRTX) Q4 earnings call, investors will likely focus on the sales performance of its cystic fibrosis medicines and updates on its non-CF pipeline candidates.
Syndax Pharmaceuticals (SNDX) Gains But Lags Market: What You Should Know
11:00pm, Wednesday, 01'st Feb 2023 Zacks Investment Research
Syndax Pharmaceuticals (SNDX) closed at $28.98 in the latest trading session, marking a +0.98% move from the prior day.
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
03:00pm, Tuesday, 31'st Jan 2023 Benzinga
Upgrades
For Silvercorp Metals Inc (AMEX:SVM), Raymond James upgraded the previous rating of Market Perform to Outperform. Silvercorp Metals earned $0.04 in the second quarter, compared to $0.08 in th
Analyst Expectations for Syndax Pharmaceuticals's Future
12:00pm, Tuesday, 31'st Jan 2023 Benzinga
Over the past 3 months, 4 analysts have published their opinion on Syndax Pharmaceuticals (NASDAQ:SNDX) stock. These analysts are typically employed by large Wall Street banks and tasked with understa
GSK Gears Up to Report Q4 Earnings: What's in the Cards?
03:00pm, Monday, 30'th Jan 2023 Zacks Investment Research
We expect GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix and Juluca to drive fourth-quarter sales.
Dr. Reddy's (RDY) Q3 Earnings & Revenues Beat Estimates
06:36pm, Friday, 27'th Jan 2023 Zacks Investment Research
Dr. Reddy's (RDY) beat earnings and revenues in the fiscal third quarter, driven by growth in the United States and Russian markets.
Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know
11:00pm, Monday, 23'rd Jan 2023 Zacks Investment Research
In the latest trading session, Syndax Pharmaceuticals (SNDX) closed at $26.47, marking a -0.45% move from the previous day.
Beat the Market Like Zacks: Boeing, Starbucks, Syndax Pharma in Focus
12:40pm, Monday, 23'rd Jan 2023 Zacks Investment Research
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
